Ovid Therapeutics (NASDAQ: OVID) chair exercises 47,333-share warrant at $1.40

Rhea-AI Filing Summary

Ovid Therapeutics Executive Chairman Jeremy M. Levin exercised a Series A warrant to acquire 47,333 shares of Common Stock at $1.40 per share. Following the exercise, he directly holds 3,735,048 shares of Common Stock.

The filing also reports 35,461 shares of Common Stock held indirectly through Divo Holdings, LLC, managed by Levin’s spouse. Levin expressly disclaims beneficial ownership of the shares held by Divo.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LEVIN JEREMY M

(Last) (First) (Middle)

C/O OVID THERAPEUTICS INC.

441 NINTH AVENUE, 14TH FLOOR

(Street)

NEW YORK NEW YORK 10001

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ovid Therapeutics Inc. [ OVID ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/23/2026		M		47,333	A	$1.4	3,735,048	D
Common Stock								35,461	I	See Footnote(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Warrant (right to buy)	$1.4	03/23/2026		M			47,333	(2)	04/17/2026	Common Stock	47,333	$0	0	D

Explanation of Responses:

1. The reportable securities are owned directly by Divo Holdings, LLC ("Divo"). The Reporting Person's spouse is the manager of Divo. The Reporting Person disclaims beneficial ownership of the shares held by Divo and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose.

2. Each Series A Warrant became immediately exercisable pursuant to the approval of the Issuer's Stockholders on December 11, 2025.

	/s/ Jeremy Levin	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did OVID Executive Chairman Jeremy Levin report?

Jeremy Levin reported exercising a Series A warrant to acquire 47,333 Ovid Therapeutics common shares at $1.40 per share. This derivative exercise converts a warrant position into actual stock and is classified as an acquisition rather than an open-market purchase or sale.

How many OVID shares does Jeremy Levin own after this Form 4 filing?

After the reported warrant exercise, Jeremy Levin directly owns 3,735,048 shares of Ovid Therapeutics common stock. The filing also shows an additional 35,461 common shares held indirectly through Divo Holdings, LLC, which are reported with a specific disclaimer of beneficial ownership.

What type of security did Jeremy Levin exercise in this OVID Form 4?

Levin exercised a Series A Warrant, which is a right to buy common stock at a fixed price. The warrant covered 47,333 underlying common shares at an exercise price of $1.40 per share, and it was exercisable following prior stockholder approval.

Does Jeremy Levin have indirect ownership of OVID shares through Divo Holdings, LLC?

The filing shows 35,461 Ovid Therapeutics shares held indirectly through Divo Holdings, LLC, managed by Levin’s spouse. However, Levin disclaims beneficial ownership of these Divo-held shares and states the report should not be viewed as an admission of beneficial ownership.

Is the OVID insider transaction a market buy or sell of common stock?

The transaction is an exercise of a derivative, not an open-market trade. Levin converted a Series A warrant into 47,333 common shares at $1.40 per share, classified as a derivative exercise/acquisition rather than a traditional market purchase or sale.

Were any Series A Warrants immediately exercisable for OVID after stockholder approval?

Yes. The filing notes that each Series A Warrant became immediately exercisable following Ovid Therapeutics stockholder approval on December 11, 2025. Levin’s March 23, 2026 exercise of 47,333 warrant shares occurred after that approval became effective.